GLUT1 (Glucose Transporter 1), encoded by the SLC2A1 gene, is the primary facilitative glucose transporter at the blood-brain barrier (BBB). As the brain consumes ~20% of total body glucose despite comprising only ~2% of body weight, GLUT1 is essential for maintaining cerebral glucose supply. GLUT1 deficiency syndrome causes epileptic encephalopathy, and reduced GLUT1 expression at the BBB is an early and consistent feature of Alzheimer's disease, preceding neuronal loss by years.
| Property | Value |
|---|---|
| Full Name | Glucose Transporter Type 1 (Solute Carrier Family 2 Member 1) |
| Gene | SLC2A1 |
| UniProt | P11166 |
| Molecular Weight | 54 kDa (glycosylated) |
| Structure | 12 transmembrane domains, Major Facilitator Superfamily |
| Subcellular Location | Plasma membrane (apical and basolateral in endothelial cells) |
| Expression | BBB endothelium, erythrocytes, astrocytic endfeet, oligodendrocytes |
| Associated Diseases | GLUT1 deficiency syndrome, Alzheimer's disease, epilepsy |
| PDB | 4PYP |
GLUT1 belongs to the Major Facilitator Superfamily (MFS) of membrane transporters. The crystal structure (solved in 2014 at 3.2 Å resolution) reveals 12 transmembrane α-helices arranged in two six-helix bundles (N-domain and C-domain) that form a central hydrophilic cavity[1]. Transport occurs via an alternating access mechanism:
Key structural features include:
GLUT1 has a Km for glucose of ~1-2 mM, well below normal blood glucose (~5 mM), ensuring near-saturation under physiological conditions. However, this means GLUT1 cannot compensate for reduced transporter density by increasing per-molecule transport rate[2].
At the BBB, GLUT1 is expressed on both the luminal (blood-facing) and abluminal (brain-facing) membranes of brain endothelial cells, mediating the transcellular transport of glucose from blood to brain interstitium. GLUT1 is also expressed on astrocytic endfeet that ensheath brain capillaries, facilitating glucose uptake into astrocytes for lactate shuttle delivery to neurons[3].
BBB GLUT1 exists as a 55 kDa glycoprotein (distinct from the 45 kDa erythrocyte isoform due to differential glycosylation). Its expression is regulated by:
GLUT1 reduction at the BBB is one of the earliest detectable abnormalities in Alzheimer's disease and in individuals at genetic risk (e.g., APOE ε4 carriers)[5]:
The hallmark glucose hypometabolism detected by ¹⁸Ffluorodeoxyglucose PET (FDG-PET) in AD — particularly in the posterior cingulate cortex, precuneus, and temporoparietal regions — is driven in part by reduced GLUT1-mediated glucose delivery across the BBB, not solely by reduced neuronal glucose utilization[6].
In mouse models, endothelial-specific GLUT1 haploinsufficiency (Slc2a1+/-) accelerates AD pathology by:
Conversely, GLUT1 overexpression in 5xFAD mice reduces Aβ plaque burden, restores cerebral glucose uptake, and improves cognitive performance, establishing a causal role for GLUT1 in AD pathogenesis[7:1].
Heterozygous loss-of-function mutations in SLC2A1 cause GLUT1 deficiency syndrome (De Vivo disease), characterized by infantile seizures, microcephaly, developmental delay, and movement disorders. CSF glucose is characteristically low (CSF:blood glucose ratio <0.4). The ketogenic diet is the standard treatment, bypassing the need for glucose transport[8].
In Parkinson's disease, FDG-PET shows relative glucose hypermetabolism in the putamen and cerebellum (compensatory) but hypometabolism in the frontal cortex. GLUT1 expression is reduced in cortical microvessels of PD patients with cognitive impairment[9].
Huntington's disease features early striatal glucose hypometabolism. Mutant huntingtin directly impairs GLUT1-mediated glucose uptake in striatal neurons, contributing to energy failure and vulnerability to excitotoxicity[10].
GLUT1 is an emerging therapeutic target in neurodegeneration:
Deng D et al. Crystal structure of the human glucose transporter GLUT1 (2014). 2014. ↩︎
Mergenthaler P et al. Sugar for the brain: the role of glucose in physiological and pathological brain function (2013). 2013. ↩︎
Simpson IA et al. Supply and demand in cerebral energy metabolism: the role of nutrient transporters (2007). 2007. ↩︎
Winkler EA et al. GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration (2015). 2015. ↩︎ ↩︎
Mosconi L et al. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease (2008). 2008. ↩︎
Landau SM et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI (2011). 2011. ↩︎
An Y et al. Evidence for brain glucose dysregulation in Alzheimer's disease (2018). 2018. ↩︎ ↩︎ ↩︎
Pascual JM et al. GLUT1 deficiency and other glucose transporter diseases (2004). 2004. ↩︎
Teune LK et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases (2010). 2010. ↩︎
Gamberino WC & Bhatt MS, Glucose transporter isoform expression and regulation in the developing and adult brain (2000). 2000. ↩︎